Key result
High-dose calcium-channel blockers improved 5-year survival in primary pulmonary hypertension patients who responded to acute vasodilator challenge compared to non-responders (94% vs 55%, P=0.003).
Why the study?
Do high doses of calcium-channel blockers improve survival in patients with primary pulmonary hypertension who respond to acute vasodilator challenge?
Cohort (n=64)
Do high doses of calcium-channel blockers improve survival in patients with primary pulmonary hypertension who respond to acute vasodilator challenge?
Absolute Event Rate: 94% vs 55%
p-value: p=0.003
High doses of calcium-channel blockers significantly improve 5-year survival in patients with primary pulmonary hypertension who demonstrate acute vasoreactivity.
No takes yet. Share an insight, caveat, or question.
May support high-dose calcium-channel blockers in vasoreactive primary pulmonary hypertension; leaves open randomized confirmation.
Rich et al. (1992) conducted a cohort in Primary pulmonary hypertension (n=64). High doses of calcium-channel blockers (nifedipine or diltiazem) vs. Non-responders and NIH Registry patients was evaluated on Survival at 5 years (p=0.003). High-dose calcium-channel blockers improved 5-year survival in primary pulmonary hypertension patients who responded to acute vasodilator challenge compared to non-responders (94% vs 55%, P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: